XM tillhandahåller inte tjänster till personer bosatta i USA.
Q
Q

QIEN


Nyheter

QIAGEN receives European IVDR certification for QIAstat-Dx syndromic testing instruments and assays

BRIEF-QIAGEN receives European IVDR certification for QIAstat-Dx syndromic testing instruments and assays Sept 26 (Reuters) - Qiagen NV QIA.DE : QIAGEN NV: GETS EUROPEAN IVDR CERTIFICATION FOR QIASTAT-DX SYNDROMIC TESTING INSTRUMENTS AND ASSAYS Source text for Eikon: ID:nGNX5rwY0C Further company coverage: QIA.DE
Q

PreAnalytiX, a QIAGEN and BD joint venture, launches novel solution for liquid biopsy from urine samples

BRIEF-PreAnalytiX, a QIAGEN and BD joint venture, launches novel solution for liquid biopsy from urine samples Sept 25 (Reuters) - Qiagen NV QIA.DE : PREANALYTIX, A QIAGEN AND BD JOINT VENTURE, LAUNCHES NOVEL SOLUTION FOR LIQUID BIOPSY FROM URINE SAMPLES Source text for Eikon: ID:nGNX3v5zxJ Further company coverage: QIA.DE
Q

Qiagen Bode Technology Would Become Exclusive Global Commercial Partner For GEDmatch Pro Genealogy Database

BRIEF-Qiagen Bode Technology Would Become Exclusive Global Commercial Partner For GEDmatch Pro Genealogy Database Sept 23 (Reuters) - Qiagen NV QIA.DE : QIAGEN NV: BODE TECHNOLOGY WOULD BECOME EXCLUSIVE GLOBAL COMMERCIAL PARTNER FOR GEDMATCH PRO GENEALOGY DATABASE Source text for Eikon: ID:nGNX4Tyd3d Further company coverage: QIA.DE
Q

Qiagen And Bio-Manguinhos/Fiocruz Collaborate To Enhance Malaria And Dengue Detection In Brazil’s National Screening Programs

BRIEF-Qiagen And Bio-Manguinhos/Fiocruz Collaborate To Enhance Malaria And Dengue Detection In Brazil’s National Screening Programs Sept 12 (Reuters) - Qiagen NV QIA.DE : QIAGEN AND BIO-MANGUINHOS/FIOCRUZ COLLABORATE TO ENHANCE MALARIA AND DENGUE DETECTION IN BRAZIL’S NATIONAL SCREENING PROGRAMS Source text for Eikon: ID:nGNX9sbmqF Further comp
Q

QIAGEN And Lilly Collaborate To Support Development Of QIAstat-Dx IVD Panel

BRIEF-QIAGEN And Lilly Collaborate To Support Development Of QIAstat-Dx IVD Panel Sept 5 (Reuters) - QIAGEN NV QIA.DE : SAID ON WEDNESDAY: QIAGEN AND LILLY COLLABORATE TO SUPPORT DEVELOPMENT OF QIASTAT-DX IVD PANEL THAT IDENTIFIES PATIENTS AT RISK FOR DEVELOPING ALZHEIMER’S DISEASE COLLABORATION SET TO LAUNCH FIRST COMMERCIALLY AVAILABLE IVD KIT
Q

Qiagen Announces Successful Placement Of New Net Share Settled Convertible Bonds

BRIEF-Qiagen Announces Successful Placement Of New Net Share Settled Convertible Bonds Sept 3 (Reuters) - QIAGEN NV QIA.DE : ANNOUNCES SUCCESSFUL PLACEMENT OF NEW NET SHARE SETTLED CONVERTIBLE BONDS REFERENCE SHARE PRICE WILL BE EQUAL TO VOLUME WEIGHTED AVERAGE PRICE OF SHARES ON NEW YORK STOCK EXCHANGE TODAY, SEPTEMBER 3, 2024 INITIAL CONVERSION P
Q

Qiagen Launches Non-Us Offering Of Net Share Settled Convertible Bonds

BRIEF-Qiagen Launches Non-Us Offering Of Net Share Settled Convertible Bonds Sept 3 (Reuters) - QIAGEN NV QIA.DE : LAUNCHES NON-US OFFERING OF NET SHARE SETTLED CONVERTIBLE BONDS COMPANY INTENDS TO ISSUE BONDS IN MINIMUM DENOMINATIONS OF USD 200,000 EACH, IN AN AGGREGATE VOLUME OF USD 450 MILLION HAVE RESOLVED TODAY TO ISSUE SENIOR, UNSECURED NET SHARE SETTLED CONVERTIBLE BONDS, WHICH MAY BE CONVERTED IN PART INTO ORDINARY SHARES OF COMPANY ("SHARES"), DUE 2031 ( " BONDS").
Q

Admiral Group, IAG, Keller Group

EUROPE RESEARCH ROUNDUP- Admiral Group, IAG, Keller Group Aug 7 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Admiral Group, IAG and Keller Group, on Wednesday. HIGHLIGHTS * Admiral Group Plc ADML.L : HSBC raises target price to 2700p from 2625p * IAG ICAG.L : Citigroup raises target price to 245p from 225p * Keller Group Plc KLR.L : Deutsche Bank raises target price to 1800p from 1550p * OCI NV OCI.AS : JP Morgan raises to overw
A
A
A
B
B
B
B
G
H
I
K
L
M
R
R
S
T
V
Q
M
R

Qiagen NV reports results for the quarter ended in June - Earnings Summary

Qiagen NV reports results for the quarter ended in June - Earnings Summary Qiagen NV QGEN.N reported quarterly adjusted earnings of 55 cents​​ per share for the quarter ended in June, higher than the same quarter last year, when the company reported EPS of 53 cents. The mean expectation of fourteen analysts for the quarter was for earnings of 51 cents per share.
Q

Qiagen Says FY Net Sales Are Expected To Be At Least $1.985 Billion CER

BRIEF-Qiagen Says FY Net Sales Are Expected To Be At Least $1.985 Billion CER July 31 (Reuters) - Qiagen NV QIA.DE : QIAGEN DELIVERS SOLID PERFORMANCE AND EXCEEDS OUTLOOK FOR Q2 2024 NET SALES WERE STABLE AT $496 MILLION IN Q2 2024 COMPARED TO Q2 2023 : HAS UPDATED ITS FY 2024 OUTLOOK FY OUTLOOK FOR ADJUSTED DILUTED EPS HAS BEEN INCREASED TO AT LEA
Q

Qiagen NV <QGEN.N> expected to post earnings of 51 cents a share - Earnings Preview

Qiagen NV expected to post earnings of 51 cents a share - Earnings Preview Qiagen NV QGEN.N , QGEN.K is expected to show a fall in quarterly revenue when it reports results on July 31 for the period ending June 30 2024 The Venlo Limburg-based company is expected to report a 0.1% decrease in revenue to $494.489 million from $494.86 million a year ago, according to the mean estimate from 13 analysts, based on LSEG data.
Q

Germany corporate earnings week ahead

DIARY-Germany corporate earnings week ahead July 26 (Reuters) - Diary of Germany (.GDAXI) corporate earnings for the week ahead GERMANY EARNINGS Start Date Start Time (GMT) RIC Company Name Event Name 30-Jul-2024 NTS 1COV.DE Covestro AG Half Year 2024 Covestro AG Earnings Release 30-Jul-2024 BMO HEIG.DE Heidelberg Materials AG Half Year 2024 Heidelberg Materials AG Earnings Release 30-Jul-2024 04:30 AIR.PA Airbus SE Half Year 2024 Airbus SE Earnings Release 31-Jul-2024 AMC QGEN.N Qiagen NV Q2 20
A
A
B
F
M
P
S
S
V
V
Q
G



Villkor

Populära tillgångar

Ansvarsfriskrivning: XM Group-enheter tillhandahåller sin tjänst enbart för exekvering och tillgången till vår onlinehandelsplattform, som innebär att en person kan se och/eller använda tillgängligt innehåll på eller via webbplatsen, påverkar eller utökar inte detta, vilket inte heller varit avsikten. Denna tillgång och användning omfattas alltid av i) villkor, ii) riskvarningar och iii) fullständig ansvarsfriskrivning. Detta innehåll tillhandahålls därför uteslutande som allmän information. Var framför allt medveten om att innehållet på vår onlinehandelsplattform varken utgör en uppmaning eller ett erbjudande om att ingå några transaktioner på de finansiella marknaderna. Handel på alla finansiella marknader involverar en betydande risk för ditt kapital.

Allt material som publiceras på denna sida är enbart avsett för utbildnings- eller informationssyften och innehåller inte – och ska inte heller anses innehålla – rådgivning och rekommendationer om finansiella frågor, investeringsskatt eller handel, dokumentation av våra handelskurser eller ett erbjudande om, eller en uppmaning till, en transaktion i finansiella instrument eller oönskade finansiella erbjudanden som är riktade till dig.

Tredjepartsinnehåll, liksom innehåll framtaget av XM såsom synpunkter, nyheter, forskningsrön, analyser, kurser, andra uppgifter eller länkar till tredjepartssajter som återfinns på denna webbplats, tillhandahålls i befintligt skick, som allmän marknadskommentar, och utgör ingen investeringsrådgivning. I den mån som något innehåll tolkas som investeringsforskning måste det noteras och accepteras att innehållet varken har varit avsett som oberoende investeringsforskning eller har utarbetats i enlighet med de rättsliga kraven för att främja ett sådant syfte, och därför är att betrakta som marknadskommunikation enligt tillämpliga lagar och föreskrifter. Se till så att du har läst och förstått vårt meddelande om icke-oberoende investeringsforskning och riskvarning om ovannämnda information, som finns här.

Riskvarning: Ditt kapital riskeras. Hävstångsprodukter passar kanske inte alla. Se vår riskinformation.